Cytokinetics Inc CYTK
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. 10-K, Item 1
- Headquarters
- South San Francisco, CA
- CEO
- Robert I. Blum
- Next results
- around Feb 23, 2027
CYTK among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
13 new risk paragraphs. 10-K filed Feb 26, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
10 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 10 checks found nothing to note
-
Receivables +6.7% ($16.6M to $17.8M) vs revenue +376.6% ($18.5M to $88.0M), -369.9 pts apart
-
Cash from operations −$510.0M vs net income −$785.0M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: Ernst & Young LLP
7 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Measurement of Revenue Participation Right Purchase Agreements; Audit; Fair Value Liabilities; Audit
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
13 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Finally, the United States and other countries have imposed and may continue to impose new trade restrictions and export regulations, have levied tariffs and taxes on certain goods, including the potential for tariffs applicable to pharmaceutical products and their inputs. In September 2025, the United States administration announced…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Any regulatory approvals that we or our partners receive for our drugs or drug candidates are subject to limitations on the indicated uses for which the drug may be marketed or require potentially costly post-marketing follow-up studies or compliance with a REMS program that includes ETASU. For example, MYQORZO is subject to a…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
If the FDA or comparable foreign regulatory authorities approve generic versions of MYQORZO, or any other potential products that receive marketing approval, or such authorities do not grant MYQORZO appropriate periods of data or market exclusivity before approving a generic version, sales of MYQORZO could be adversely affected. Once an…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Disruptions at the FDA, including due to a reduction in the FDA’s workforce and/or inadequate funding for the FDA, could prevent the FDA from performing normal functions on which our business relies, which could negatively impact our business. The ability of the FDA to review and approve new products or review other regulatory…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $94.6M | $7.5M | $18.5M | $88.0M |
| Net income | −$389.0M | −$526.2M | −$589.5M | −$785.0M |
| Operating cash flow | −$299.5M | −$414.3M | −$395.9M | −$510.0M |
| Free cash flow | −$310.9M | −$415.7M | −$399.8M | −$534.8M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$88.0M ▲ 376.6% in FY2025−$785.0M in FY2025−$534.8M in FY2025
Recent filings
11 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 9, 2026B LYNNE PARSHALL (Director) gave notice of a planned sale of 5,000 shares worth about $268K Form 144, approximate sale date Nov 9, 2026, under a 10b5-1 plan adopted Aug 10, 2026
-
Planned saleNov 4, 2026B. Lynne Parshall (member of our board of directors) adopted a 10b5-1 trading plan reported in the 10-Q, up to 20,000 shares, runs to Sep 3, 2027
-
Planned saleNov 4, 2026Fady I. Malik (Executive Vice President, Research and Development) adopted a 10b5-1 trading plan reported in the 10-Q, up to 144,075 shares, runs to Dec 21, 2027
-
Planned saleNov 4, 2026John T. Henderson (Chairman of our board of directors) adopted a 10b5-1 trading plan reported in the 10-Q, up to 28,064 shares, runs to May 18, 2027
-
Planned saleNov 4, 2026Andrew Callos (Executive Vice President, Chief Commercial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 67,414 shares, runs to Dec 1, 2027
About the company
Cytokinetics Inc, South San Francisco, CA · from the 10-K filed Feb 26, 2026
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. Our first commercial product is MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, and 20 mg tablets, which the FDA approved in December 2025. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity.
- Headquarters
- South San Francisco, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CYTK/export.csv") into a cell.